| 1. |
Indian Patent and title of the invention is “Daclatasvir Hydrochloride Tablet Formulation and Preparation Thereof”. Applicant Position was 1, Number of Claims were 9, Application Issue No: 202321043607A and the Patent office Journal No: 31/2023 Dated 04.08.2023, Part-I, 51984. |
| 2. |
Indian Patent and title of the invention is “RP-UPLC Method for Estimation of Brexpiprazole in Pharmaceutical Dosage Form and Uses Thereof”. Applicant Position was 4, Number of Claims were 6, Application Issue No: 202341023099A and the Patent office Journal No: 17/2023 Dated 28.04.2023, Part-I, 33224. |
| 3. |
Indian Patent and title of the invention is “Nanosuspension of Maribavir and Preparation Method Thereof”. Applicant Position was 4, Number of Claims were 8, Application No: 202341013767A and the Patent office Journal Issue No: 11/2023, 17.03.2023, Part-II, 27392. |
| 4. |
Indian Patent and title of the invention is “Bilayer Tablet Formulation of Viloxazine Hydrochloride and Preparation Method Thereof”. Applicant Position was 1, Number of Claims were 6, Application No: 202341007187A and the Patent office Journal Issue No: 06/2023, 10.02.2023, Part-I, 9940. |
| 5. |
Indian Patent and title of the invention is “Mazus Pumilus Leaf Extract and Preparation Method Thereof with Anticancer Activity”. Applicant Position was 3, Number of Claims was 4, Application No: 202341005654A and the Patent office Journal Issue No: 06/2023, 10.02.2023, Part-I, 9889. |
| 6. |
Indian Patent and title of the invention is “Advancement of Drug Delivery Systems Based on Nanotechnology and Green Chemistry: Green Nanomedicines”. Applicant Position was 4, Number of Claims were 7, Application No: 202241056521A and the Patent office Journal Issue No: 41/2022, 14.10.2022, Part-I, 65609. |
| 7. |
Indian Patent and title of the invention is “HPLC Method for Estimation of Oliceridine in Pharmaceutical Dosage Form and Uses Thereof”. Applicant Position was 2, Number of Claims were 3, Application No: 202241074455A and the Patent office Journal Issue No: 52/2022, 30.12.2022, Part-III, 83041. |
